Method for treating ifnalpha related conditions
AssigneeNeovacs
InventorsGeraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIERE, Camille ROUCAIROL
Life of this patent
Estimating the term…
Abstract
An immunogenic product including IFNα coupled to a carrier protein molecule is capable to induce in vivo anti-IFNα antibodies and is useful in treating IFNα related conditions.
Claims17
1-3. (canceled)
A method for treating an IFNα related condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an immunogenic product comprising IFNα coupled to a carrier protein molecule, wherein said therapeutically effective amount is more than 30 mcg of immunogenic product per administration.
A unit dosage form comprising more than 30 mcg of an immunogenic product comprising IFNα coupled to a carrier protein molecule.
A medical device comprising more than 30 mcg of an immunogenic product comprising IFNα coupled to a carrier protein molecule.
A kit comprising at least one vial containing more than 30 mcg of an immunogenic product comprising IFNα coupled to a carrier protein molecule, at least one vial containing adjuvant, and means for contacting said immunogenic product to the adjuvant, and for emulsifying the mixture with the adjuvant.
Dependencies are inferred from the claim text.